Participant flow

Milademetan in Advanced/Metastatic Solid Tumors · Source last updated 2024-10-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   260 mg once daily (QD) orally on Days 1 to 3 and Days 15 to 17 of each 28-day cycle

   id

   FG000

   title

   Milademetan (RAIN-32)

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         10

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         9

      type

      Physician Decision

   3. reasons

      1. group Id

         FG000

         num Subjects

         5

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         2

      type

      Lost to Follow-up

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         40

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         14

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         26

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

All enrolled participants (40 participants) received the study medication. Twenty-eight (28) discontinued treatment. Fourteen (14) completed the study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice